Search

Your search keyword '"Luttwak, Efrat"' showing total 146 results
Start Over Author "Luttwak, Efrat"
146 results on '"Luttwak, Efrat"'

1. Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma

Author

Leithner, Doris, Flynn, Jessica R., Devlin, Sean M., Mauguen, Audrey, Fei, Teng, Zeng, Shang, Zheng, Junting, Imber, Brandon S., Hubbeling, Harper, Mayerhoefer, Marius E., Bedmutha, Akshay, Luttwak, Efrat, Corona, Magdalena, Dahi, Parastoo B., Luna de Abia, Alejandro, Landego, Ivan, Lin, Richard J., Palomba, M. Lia, Scordo, Michael, Park, Jae H., Tomas, Ana Alarcon, Salles, Gilles, Lafontaine, Daniel, Michaud, Laure, Shah, Gunjan L., Perales, Miguel-Angel, Shouval, Roni, and Schöder, Heiko

Published
2024
Full Text
View/download PDF

2. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Author

Avivi, Irit, Perry, Chava, Segman, Yafit, Amit, Odelia, Bar-On, Yaeli, Katz, Ofrat Beyer, Gold, Ronit, Ribakovsky, Elena, Avigdor, Abraham, Vainstein, Vladimir, Goldschmidt, Neta, Ringelstein-Harlev, Shimrit, Horowitz, Netanel A., Gutwein, Odit, Gurion, Ronit, Itchaki, Gilad, Abadi, Uri, Nemets, Anatoly, Sofer, Orit, Vezker, Miri, Tadmor, Tamar, Dally, Najib, Filanovsky, Kalman, Leiba, Merav, Sarid, Nadav, Benyamini, Noam, Luttwak, Efrat, Herishanu, Yair, and Ram, Ron

Published
2022
Full Text
View/download PDF

5. Impact of Tocilizumab on CAR-T Cells Outcome and Toxicity: Results from a Large B Cell Lymphoma Cohort

Author

Cassanello, Giulio, primary, Devlin, Sean M., additional, Landego, Ivan, additional, de Abia, Alejandro Luna, additional, Corona, Magdalena, additional, Rivas-Delgado, Alfredo, additional, Luttwak, Efrat, additional, Parascondola, Allison, additional, Saldia, Amethyst, additional, Dahi, Parastoo B., additional, Lin, Dr. Richard J., additional, Palomba, M. Lia, additional, Park, Jae H., additional, Salles, Gilles, additional, Perales, Miguel-Angel, additional, Scordo, Michael, additional, Shouval, Roni, additional, and Shah, Gunjan, additional

Published
2024
Full Text
View/download PDF

6. Digital Droplet PCR Based Monitoring of CAR-T Cell Expansion in Lymphoma Patients: Impact on Treatment Outcome

Author

Cassanello, Giulio, primary, Borsu, Laetitia, additional, Arcila, Maria E., additional, Yao, JinJuan, additional, Momeni-Boroujeni, Amir, additional, Ewalt, Mark D, additional, Patel, Utsav, additional, Chan, Roger, additional, Gray, Brandon, additional, de Abia, Alejandro Luna, additional, Corona, Magdalena, additional, Luttwak, Efrat, additional, Rivas-Delgado, Alfredo, additional, Landego, Ivan, additional, Parascondola, Allison, additional, Saldia, Amethyst, additional, Flynn, Jessica, additional, Devlin, Sean M., additional, Dahi, Parastoo B., additional, Lin, Dr. Richard J., additional, Palomba, M. Lia, additional, Scordo, Michael, additional, Shouval, Roni, additional, Salles, Gilles, additional, Perales, Miguel-Angel, additional, and Shah, Gunjan, additional

Published
2024
Full Text
View/download PDF

7. Site-Specific Response Rates in Large B-Cell Lymphomas Treated with CD19-CART Therapy.

Author

Luna, Alejandro, primary, Corona, Magdalena, additional, Flynn, Jessica, additional, Devlin, Sean M., additional, Luttwak, Efrat, additional, Landego, Ivan, additional, Dahi, Parastoo B., additional, Lin, Dr. Richard J., additional, Parascondola, Allison, additional, Palomba, M. Lia, additional, Shah, Gunjan L., additional, Scordo, Michael, additional, Imber, Brandon S., additional, Tomas, Ana Alarcón, additional, Salles, Gilles, additional, Park, Jae H., additional, Perales, Miguel-Angel, additional, and Shouval, Roni, additional

Published
2024
Full Text
View/download PDF

9. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Author

Cohen, Yael C., Zada, Mor, Wang, Shuang-Yin, Bornstein, Chamutal, David, Eyal, Moshe, Adi, Li, Baoguo, Shlomi-Loubaton, Shir, Gatt, Moshe E., Gur, Chamutal, Lavi, Noa, Ganzel, Chezi, Luttwak, Efrat, Chubar, Evgeni, Rouvio, Ory, Vaxman, Iuliana, and Pasvolsky, Oren

Subjects
Oncology, Experimental, Molecular dynamics -- Research, Drug resistance -- Research, Multiple myeloma -- Drug therapy -- Patient outcomes, Cancer -- Relapse -- Research, Biological sciences, Health
Abstract

Multiple myeloma (MM) is a neoplastic plasma-cell disorder characterized by clonal proliferation of malignant plasma cells. Despite extensive research, disease heterogeneity within and between treatment-resistant patients is poorly characterized. In the present study, we conduct a prospective, multicenter, single-arm clinical trial (NCT04065789), combined with longitudinal single-cell RNA-sequencing (scRNA-seq) to study the molecular dynamics of MM resistance mechanisms. Newly diagnosed MM patients (41), who either failed to respond or experienced early relapse after a bortezomib-containing induction regimen, were enrolled to evaluate the safety and efficacy of a daratumumab, carfilzomib, lenalidomide and dexamethasone combination. The primary clinical endpoint was safety and tolerability. Secondary endpoints included overall response rate, progression-free survival and overall survival. Treatment was safe and well tolerated; deep and durable responses were achieved. In prespecified exploratory analyses, comparison of 41 primary refractory and early relapsed patients, with 11 healthy subjects and 15 newly diagnosed MM patients, revealed new MM molecular pathways of resistance, including hypoxia tolerance, protein folding and mitochondria respiration, which generalized to larger clinical cohorts (CoMMpass). We found peptidylprolyl isomerase A (PPIA), a central enzyme in the protein-folding response pathway, as a potential new target for resistant MM. CRISPR-Cas9 deletion of PPIA or inhibition of PPIA with a small molecule inhibitor (ciclosporin) significantly sensitizes MM tumor cells to proteasome inhibitors. Together, our study defines a roadmap for integrating scRNA-seq in clinical trials, identifies a signature of highly resistant MM patients and discovers PPIA as a potent therapeutic target for these tumors. Integration of longitudinal single-cell analysis of relapsed and refractory multiple myeloma patients in a prospective clinical trial uncovers new pathways of drug resistance and identifies potential actionable targets., Author(s): Yael C. Cohen [sup.1] [sup.2] , Mor Zada [sup.1] [sup.3] , Shuang-Yin Wang [sup.3] , Chamutal Bornstein [sup.3] , Eyal David [sup.3] , Adi Moshe [sup.3] , Baoguo Li [...]

Published
2021
Full Text
View/download PDF

10. Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

Author

Cassanello, Giulio, primary, Borsu, Laetitia, additional, Arcila, Maria E., additional, Yao, Jinjuan, additional, Momeni Boroujeni, Amir, additional, Ewalt, Mark, additional, Patel, Utsav, additional, Chan, Roger, additional, Gray, Brandon, additional, Luna De Abia, Alejandro, additional, Corona, Magdalena, additional, Luttwak, Efrat, additional, Landego, Ivan, additional, Parascondola, Allison, additional, Saldia, Amethyst, additional, Palomba, Maria Lia, additional, Alarcon Tomas, Ana, additional, Flynn, Jessica R, additional, Devlin, Sean M., additional, Dahi, Parastoo B., additional, Lin, Richard J., additional, Scordo, Michael, additional, Shouval, Roni, additional, Salles, Gilles, additional, Perales, Miguel-Angel, additional, and Shah, Gunjan L., additional

Published
2023
Full Text
View/download PDF

12. Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients.

Author

Avivi, Irit, Shragai, Tamir, Luttwak, Efrat, Trestman, Svetlana, and Cohen, Yael C.

Subjects
MULTIPLE myeloma, OCULAR toxicology, PROGRESSION-free survival, OVERALL survival, TREATMENT delay (Medicine)
Abstract

Objectives: To evaluate whether low‐dose belantamab mafodotin (B‐MAF) dosing results in lower toxicity and better overall outcome. Methods: We retrospectively evaluated nine consecutive patients treated with low‐dose (1.9 mg/kg) B‐MAF. Results: The median age was 70 years. Most patients were penta‐refractory. Ocular toxicity was observed in 77.7%. Adverse events resulting in treatment delays were recorded in 9 out of 124 cycles being given. Overall response rate was 66% (6/9), and all responding patients achieved very good partial response or better. Within a median follow‐up of 12 (range 0.5–13.8) months, median progression‐free survival and overall survival were 14 (CI95% 6–22) and 20 (95%CI 0–41) months, respectively. Conclusion: Low‐dose B‐MAF regimen showed high‐efficacy and low‐toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. POSTER: MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sectional Historical Cohort Study

Author

Cohen, Inbar, primary, Vaxman, Iuliana, additional, Zamir, Itai, additional, Fridberg, Gil, additional, Shragai, Tamir, additional, Trestman, Svetlana, additional, Baran, Tomer Ziv, additional, Luttwak, Efrat, additional, Shmuel, Ronit, additional, Melamed, Natan, additional, Avivi, Irit, additional, Raanani, Pia, additional, Dispenzieri, Angela, additional, Gertz, Morie A., additional, and Cohen, Yael C., additional

Published
2023
Full Text
View/download PDF

14. MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sectional Historical Cohort Study

Author

Cohen, Inbar, primary, Vaxman, Iuliana, additional, Zamir, Itai, additional, Fridberg, Gil, additional, Shragai, Tamir, additional, Trestman, Svetlana, additional, Baran, Tomer Ziv, additional, Luttwak, Efrat, additional, Shmuel, Ronit, additional, Melamed, Natan, additional, Avivi, Irit, additional, Raanani, Pia, additional, Dispenzieri, Angela, additional, Gertz, Morie A., additional, and Cohen, Yael C., additional

Published
2023
Full Text
View/download PDF

15. Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes

Author

Ghione, Paola, primary, Ahsanuddin, Salma, additional, Luttwak, Efrat, additional, Varela, Sabela Bobillo, additional, Nakajima, Reiko, additional, Michaud, Laure, additional, Gupta, Kanika, additional, Navitski, Anastasia, additional, Straus, David, additional, Palomba, M. Lia, additional, Moskowitz, Alison, additional, Noy, Ariela, additional, Hamlin, Paul, additional, Matasar, Matthew, additional, Kumar, Anita, additional, Falchi, Lorenzo, additional, Yahalom, Joachim, additional, Horwitz, Steven, additional, Zelenetz, Andrew, additional, Younes, Anas, additional, Salles, Gilles, additional, Schöder, Heiko, additional, and Joffe, Erel, additional

Published
2023
Full Text
View/download PDF

16. P942: MULTIPLE MYELOMA OLIGOSECRETORY RELAPSE- A CROSS SECTIONAL HISTORICAL COHORT STUDY

Author

Vaxman, Iuliana, primary, Zamir, Itai, additional, Cohen, Inbar, additional, Fridberg, Gil, additional, Shragai, Tamir, additional, Trestman, Svetlana, additional, Ziv, Tomer, additional, Luttwak, Efrat, additional, Shmuel, Ronit, additional, Melamed, Natan, additional, Levi, Shai, additional, Avivi, Irit, additional, Raanani, Pia, additional, Dispenzieri, Angela, additional, Gertz, Morie, additional, and Cohen, Yael, additional

Published
2023
Full Text
View/download PDF

17. P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY.

Author

Moshe, Yakir, primary, Levi, Shai, additional, Neeman, Miri, additional, Gat, Roi, additional, Levi, Mor, additional, Eilati, Nili, additional, Shragai, Tamir, additional, Basood, May, additional, Segman, Yafit, additional, Baron, Yaeli, additional, Luttwak, Efrat, additional, Neuman, Tsipora, additional, Vitkon, Roy, additional, Mittelman, Moshe, additional, and Avivi, Irit, additional

Published
2023
Full Text
View/download PDF

20. Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study

Author

Beyar Katz, Ofrat, primary, Perry, Chava, additional, Grisariu‐Greenzaid, Sigal, additional, Yehudai‐Ofir, Dana, additional, Luttwak, Efrat, additional, Avni, Batia, additional, Zuckerman, Tsila, additional, Sdayoor, Inbal, additional, Stepensky, Polina, additional, Ringelstein‐Harlev, Shimrit, additional, Bar‐On, Yael, additional, Libster, Diana, additional, Sharvit, Liat, additional, Amit, Odelia, additional, Greenbaum, Uri, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Avivi, Irit, additional, and Ram, Ron, additional

Published
2023
Full Text
View/download PDF

22. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Author

Beyar-Katz, Ofrat, primary, Perry, Chava, additional, Bar-On, Yael, additional, Grisariu, Sigal, additional, Yehudai-Ofir, Dana, additional, Luttwak, Efrat, additional, Avni, Batia, additional, Zuckerman, Tsila, additional, Sdayoor, Inbal, additional, Stepensky, Polina, additional, Ringelstein-Harlev, Shimrit, additional, Libster, Diana, additional, Sharvit, Liat, additional, Amit, Odelia, additional, Greenbaum, Uri, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Avivi, Irit, additional, and Ram, Ron, additional

Published
2022
Full Text
View/download PDF

23. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Author

Beyar Katz, Ofrat, primary, Perry, Chava, additional, Luttwak, Efrat, additional, Sdayoor, Inbal, additional, Bar-On, Yael, additional, Amit, Odelia, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Grisariu Greenzaid, Sigal, additional, Avni, Batia, additional, Stepensky, Polina, additional, Libster, Diana, additional, Yehudai-Ofir, Dana, additional, Harlev, Shimrit, additional, Sharvit, Liat, additional, Zuckerman, Tsila, additional, Greenbaum, Uri, additional, Avivi, Irit, additional, and Ram, Ron, additional

Published
2022
Full Text
View/download PDF

24. Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Author

Cohen, Yael C, primary, Gatt, Moshe E, additional, Luttwak, Efrat, additional, Lavi, Noa, additional, Ganzel, Chezi, additional, Chubar, Evgeni, additional, Rouvio, Ory, additional, Vaxman, Iuliana, additional, Pasvolsky, Oren, additional, Ballan, Mouna, additional, Tadmor, Tamar, additional, Nemets, Anatoly, additional, Jarchowsky, Osnat, additional, Shvetz, Olga, additional, Shpilberg, Ofer, additional, Dally, Najib, additional, Leiba, Merav, additional, Weiner, Assaf, additional, Zada, Mor, additional, Wang, Shuang-Yin, additional, Gur, Chamutal, additional, Lowenton-Spier, Noa, additional, Goor-Porges, Liron, additional, Amit, Ido, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

25. A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Author

Cohen, Yael C, primary, Shragai, Tamir, additional, Lavi, Noa, additional, Vaxman, Iuliana, additional, Chubar, Evgeni, additional, Gatt, Moshe E, additional, Ganzel, Chezi, additional, Magen, Hila, additional, Luttwak, Efrat, additional, Lowenton-Spier, Noa, additional, Gez-Aaronson, Liron, additional, Melamed, Natan, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

26. P-114: Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study

Author

Shragai, Tamir, primary, Magen, Hila, additional, Lavi, Noa, additional, Gatt, Moshe, additional, Trestman, Svetlana, additional, Zektser, Miri, additional, Ganzel, Chezi, additional, Jarchowsky, Osant, additional, Berger, Tamar, additional, Tadmor, Tamar, additional, Leiba, Merav, additional, Hertzog-Zarfaty, Katrin, additional, Horowitz, Netanel, additional, Shapira, Michael, additional, Varssano, David, additional, Berger, Yoav, additional, Frenkel, Shahar, additional, Krauthammer, Mark, additional, Avivi, Irit, additional, Luttwak, Efrat, additional, and Cohen, Yael, additional

Published
2022
Full Text
View/download PDF

29. COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Author

Bronstein, Yotam, primary, Gat, Roi, additional, Levi, Shai, additional, Cohen, Yael C., additional, Luttwak, Efrat, additional, Benyamini, Noam, additional, Shragai, Tamir, additional, Vitkon, Roy, additional, Neaman, Miriam, additional, Eilaty, Nili, additional, Levi, Mor, additional, Trestman, Svetlana, additional, Perry, Chava, additional, Herishanu, Yair, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

30. Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.

Author

Shragai, Tamir, Magen, Hila, Lavi, Noa, Gatt, Moshe, Trestman, Svetlana, Zektser, Miri, Ganzel, Chezi, Jarchowsky, Osnat, Berger, Tamar, Tadmor, Tamar, Leiba, Merav, Hertzog‐Tzarfaty, Katrin, Horowitz, Netanel, Shapira, Michael, Varssano, David, Berger, Yoav, Frenkel, Shahar, Krauthammer, Mark, Avivi, Irit, and Luttwak, Efrat

Subjects
MULTIPLE myeloma, OCULAR toxicology, PROGRESSION-free survival, RETROSPECTIVE studies, OVERALL survival
Abstract

Summary: Belantamab mafodotin, an immuno‐conjugate targeting B‐cell maturation antigen, showed single‐agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real‐world data and long‐term follow‐up are scarce. We conducted a multisite retrospective study aimed to assess safety and efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One‐hundred and six RRMM patients were treated with belantamab mafodotin between July 2019 and March 2021. The median age was 69.4 years. Patients were heavily pretreated with a median of six (range 2–11) prior therapy lines. Major adverse effects included ocular toxicity (keratopathy 68.4%, grade ≥3: 40.5%; blurred vision 36.8%, grade ≥3: 6.3%), thrombocytopenia (27.4%, grade ≥3: 17.9%) and infections (11.3%, grade ≥3: 7.5%). Median follow‐up time was 11.9 [95% confidence interval (CI) 10.0–13.8] months. Overall response rate was 45.5%. Median progression‐free survival was 4.7 (95% CI 3.5–5.9) months in the entire cohort and 8.8 (95% CI 6.6–10.9) months among responders. Median overall survival was 14.5 (95% CI 9.5–19.6) months, and not reached for responders. To conclude, in a real‐world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma

Author

Avivi, Irit, primary, Balaban, Roi, additional, Shragai, Tamir, additional, Sheffer, Gabi, additional, Morales, Miguel, additional, Aharon, Anat, additional, Lowenton‐Spier, Noa, additional, Trestman, Svetlana, additional, Perry, Chava, additional, Benyamini, Noam, additional, Mittelman, Moshe, additional, Tabib, Yaara, additional, Bar Lev, Tali, additional, Zavaro, Mor, additional, Herishanu, Yair, additional, Luttwak, Efrat, additional, and Cohen, Yael C., additional

Published
2021
Full Text
View/download PDF

41. Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review

Author

Shragai, Tamir, primary, Gatt, Moshe, additional, Lavie, Noa, additional, Vaxman, Iuliana, additional, Tadmor, Tamar, additional, Rouvio, Ory, additional, Zektser, Miri, additional, Horowitz, Nethanel, additional, Magen, Hila, additional, Ballan, Mouna, additional, Suru, Celia, additional, Luttwak, Efrat, additional, Levi, Shai, additional, Ziv‐Baran, Tomer, additional, Avivi, Irit, additional, and Cohen, Yael C., additional

Published
2020
Full Text
View/download PDF

42. Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study

Author

Luttwak, Efrat, primary, Gatt, Moshe E., additional, Lebel, Eyal, additional, Lavi, Noa, additional, Tadmor, Tamar, additional, Natalia, Kreiniz, additional, Benyamini, Noam, additional, Horowitz, Netanel, additional, Geva, Mika, additional, Suriu, Celia, additional, Avivi, Irit, additional, Trestman, Svetlana, additional, Mittelman, Moshe, additional, Rouvio, Ory, additional, and Cohen, Yael C., additional

Published
2020
Full Text
View/download PDF

43. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.

Author

Cohen, Dan, Luttwak, Efrat, Beyar-Katz, Ofrat, Hazut Krauthammer, Shir, Bar-On, Yael, Amit, Odelia, Gold, Ronit, Perry, Chava, Avivi, Irit, Ram, Ron, and Even-Sapir, Einat

Subjects
*PROGRESSION-free survival, *DIFFUSE large B-cell lymphomas, *B cell lymphoma, *PATIENT selection, *CELLULAR therapy, *CHIMERIC antigen receptors, *STATISTICS, *MULTIVARIATE analysis, *CELL receptors, *CANCER patients, *PRE-tests & post-tests, *TREATMENT effectiveness, *RADIOPHARMACEUTICALS, *POSITRON emission tomography, *SURVIVAL analysis (Biometry), *DESCRIPTIVE statistics, *DEOXY sugars, *COMPUTED tomography, *T cells
Abstract

Purpose: The introduction of CD19-specific chimeric antigen receptor T-cell therapy (CAR-T) for treatment of relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) gives hope to patients with otherwise dismal prognosis. Therapy outcomes, however, depend upon selection of patients and accurate early identification of non-responders. Patients treated with CAR-T usually undergo [18F]FDG PET-CT at time of decision (TD), time of CAR-T transfusion (TT), 1 month (M1), and 3 months (M3) post-therapy. The purpose of the current study was to identify the specific parameters that should be addressed when reporting PET-CT studies in the clinical setting of CAR-T therapy. Methods: A total of 138 PET-CT scans (30 TD, 42 TT, 44 M1, 22 M3) of 48 patients treated with CAR-T were included. SUVmax, TMTV, and TLG were calculated in all scans. Response was assessed using the Deauville scale and ΔSUVmax method. Overall survival (OS) was the primary endpoint. Median follow-up was 12.8 (IQR 6.4–16.0) months from CAR-T infusion. Results: In a univariate analysis, TD-SUVmax > 17.1 and TT-SUVmax > 12.1 were associated with shorter OS (Pv < 0.05). In a multivariate analysis, three factors were significantly associated with shorter OS: TD-SUVmax > 17.1 (HR 10.3; Pv < 0.01), LDH > 450 U/l (HR 7.7; Pv < 0.01), and ECOG score > 1 (HR 5.5; Pv = 0.04). Data from TD and TT PET-CT scans were not predictive of toxicity. On M1-PET-CT, patients with a Deauville score > 3 had significantly shorter OS (median 7.9 months, versus not reached, Pv < 0.01). ΔSUVmax ≤ 66% on M1-PET-CT predicted shorter OS when M1-SUVmax was compared to TD-SUVmax (Pv = 0.02) but not to TT-SUVmax (Pv = 0.38). Conclusion: Pre-treatment SUVmax may guide patient selection for CAR-T therapy. On M1-PET-CT, Deauville score and ΔSUVmax from TD may identify early therapy failure. These parameters are easy to obtain and should be included in the PET-CT report. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. Outcomes of Post-Induction Bortezomib Therapy in Patients with Newly diagnosed Multiple Myeloma: A Multi-Center Retrospective Observational Study

Author

Luttwak, Efrat, primary, Gatt, Moshe, additional, Lavi, Noa, additional, Tadmor, Tamar, additional, Kreiniz, Natalia, additional, Benyamini, Noam, additional, Horowitz, Netanel, additional, Suriu, Celia, additional, Avivi, Irit, additional, Trestman, Svetlana, additional, Mittelman, Moshe, additional, Ram, Ron, additional, Rouvio, Ory, additional, and Cohen, Yael, additional

Published
2019
Full Text
View/download PDF

47. Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review.

Author

Shragai, Tamir, Gatt, Moshe, Lavie, Noa, Vaxman, Iuliana, Tadmor, Tamar, Rouvio, Ory, Zektser, Miri, Horowitz, Nethanel, Magen, Hila, Ballan, Mouna, Suru, Celia, Luttwak, Efrat, Levi, Shai, Ziv‐Baran, Tomer, Avivi, Irit, and Cohen, Yael C.

Subjects
AMYLOIDOSIS, CLINICAL trials, MULTIVARIATE analysis, PROGRESSION-free survival, DARATUMUMAB
Abstract

Objectives: Patients with relapsed/refractory AL amyloidosis (RRAL) have poor prognosis, but emerging data shows promising results with the use daratumumab. We evaluated daratumumab treatment in RRAL in real‐world setting. Methods: A retrospective multisite study of RRAL patients treated with daratumumab alone and in combinations. Results: Forty‐nine patients, diagnosed between 1.1.2008 and 1.2.2018 were included; 27% also had multiple myeloma (MM). Revised Mayo score was ≥ 3 in 67%. Hematologic overall response rate was 81%, 64% achieved very good partial response (VGPR) or better. Concurrent active MM was associated with lower rates of VGPR (OR 0.19, 95% CI 0.04‐0.81; P =.03) in a multi‐variate analysis. Cardiac and renal responses were 74% and 73%, respectively. Median progression‐free survival (PFS) was 28.4 months and median overall survival (OS) was not reached; 2‐year PFS and OS were 68.6 ± 7.5% and 90.4 ± 4.6%, respectively. Hematologic response correlated with prolonged PFS and OS. Daratumumab was safe and well tolerated, no patients discontinued therapy due to toxicity. Our data was aligned with outcomes from a systematic literature review, which identified 10 case series (n = 517) and 2 clinical trials (n = 62) meeting prespecified criteria. Conclusions: Our data support favorable safety tolerability and efficacy of daratumumab among non‐selective RRAL patients in a real‐world setting. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. 18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma

Author

Leithner, Doris, Flynn, Jessica R., Devlin, Sean M., Mauguen, Audrey, Fei, Teng, Zeng, Shang, Imber, Brandon S., Hubbeling, Harper, Mayerhoefer, Marius, Luttwak, Efrat, Corona, Magdalena, Dahi, Parastoo Bahrami, Luna De Abia, Alejandro, Landego, Ivan, Lin, Richard J., Palomba, Maria Lia, Scordo, Michael, Alarcon Tomas, Ana, Salles, Gilles, Lafontaine, Daniel, Michaud, Laure, Shah, Gunjan L., Perales, Miguel-Angel, Schoder, Heiko, and Shouval, Roni

Abstract

Introduction:CAR-T cell therapy has transformed the care of patients with large-B-cell lymphoma (LBCL), but disease relapse and toxicities remain clinical challenges, while effective quantitative biomarkers are lacking. Our aim was to determine the role of 18F-FDG PET/CT imaging features as biomarkers in LBCL treated with CD19 CAR-T cell therapy.

Published
2023
Full Text
View/download PDF

49. A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Author

Cohen, Yael C., Shragai, Tamir, Lavi, Noa, Vaxman, Iuliana, Chubar, Evgeni, Gatt, Moshe E, Ganzel, Chezi, Magen, Hila, Luttwak, Efrat, Mittelman, Moshe, Tzoran, Inna, Vainstein, Vladimir, Lowenton-Spier, Noa, Melamed, Natan, Krayzler, Ella, Pereg, Ilana, and Avivi Mazza, Irit

Abstract

Introduction:

Published
2023
Full Text
View/download PDF

50. Impact of Early Histological Transformation on Survival in Patients with Follicular Lymphoma

Author

Luttwak, Efrat, Qiu, Annie, Okwali, Michelle, Rivas-Delgado, Alfredo, Isgor, Irem, Boardman, Alexander P., Caron, Philip, David, Kevin A., Falchi, Lorenzo, Ghione, Paola, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Lue, Jennifer Kimberly, Moskowitz, Alison, Noy, Ariela, Galera, Pallavi, Palomba, M. Lia, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Schoder, Heiko, Yahalom, Joachim, Dogan, Ahmet, and Salles, Gilles

Abstract

Introduction:FL represents the second most common NHL with an indolent natural history and a median OS exceeding 20 y. Histologic transformation (HT) to an aggressive lymphoma is historically linked to poor outcomes with a median post-transformation survival of 2-5 y. EFS24 and POD24 are established adverse events indicating a poor overall survival. POD24 is associated with a higher incidence of HT following immunochemotherapy. However, the impact of HT within POD24 (HT24) remains unknown.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results